Tubulysin and protein-tubulysin conjugates
Tubulysin-based protein conjugates effectively address resistance mechanisms in ADCs by disrupting cancer cell division, providing potent anti-cancer activity against multidrug-resistant tumors.
JP7590328B2Active Publication Date: 2024-11-26REGENERON PHARMACEUTICALS INC
Patent Information
- Application Number
- JP2021535783
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-21
- Filing Date
- 2019-12-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-12-20
Smart Images

Figure 0007590328000877 
Figure 0007590328000878 
Figure 0007590328000879
Abstract
Provided herein are compounds, compositions, and methods for the treatment of cancer-related diseases and disorders, including tubulysin and protein (eg, antibody) drug conjugates thereof.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Method for producing tubulicin derivatives and their complexes
JP2015518473A
Tubricin compounds, their production and use methods
JP2016509021A
Tubulysine derivatives
US20120129779A1
